Overview

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Status:
Terminated

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the course of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy

Phase:

Phase 2

Details

Lead Sponsor:

Alder Biopharmaceuticals, Inc.
CSL Behring